文献速递呼吸道感染呼吸危重症与机械通气

免疫抑制对呼吸机相关性下呼吸道感染发生率、病原学及结局的影响

Impact of immunosuppression on incidence, aetiology and outcome of ventilator-associated lower respiratory tract infections.
PubMed 文献 · Eur Respir J · 2018-03-08

该研究基于前瞻性多国TAVeM数据库,比较免疫抑制患者(n=663)与非免疫抑制患者(n=2297)呼吸机相关性下呼吸道感染(VA-LRTI)的发生率、病原学及结局。免疫抑制患者VA-LRTI发生率显著更低(16.6% vs 24.2%),但合并VA-LRTI时多重耐药菌比例(72% vs 59%)和ICU死亡率(54% vs 30%)显著更高。

要点

  • 免疫抑制患者VA-LRTI发生率显著低于非免疫抑制患者(16.6% vs 24.2%)。
  • 免疫抑制患者发生VA-LRTI时多重耐药菌比例更高(72% vs 59%)。
  • 免疫抑制合并VA-LRTI者ICU死亡率更高(54% vs 30%,OR 2.68)。

核心结论

  • 免疫抑制患者VA-LRTI发生率显著更低,但一旦发生则死亡风险显著更高。
  • 免疫抑制患者VA-LRTI中多重耐药病原体更常见。

研究设计与样本

  • 基于前瞻性多国TAVeM数据库的计划分析。
  • 纳入机械通气>48小时的患者,免疫抑制组n=663,非免疫抑制组n=2297。

主要发现

  • VA-LRTI发生率免疫抑制组16.6% vs 非免疫抑制组24.2%(sub-hazard ratio 0.65,95% CI 0.53-0.80;p<0.0001)。
  • 呼吸机相关性气管支气管炎发生率7.3% vs 11.6%(sub-hazard ratio 0.61,95% CI 0.45-0.84;p=0.002)。
  • 呼吸机相关性肺炎发生率9.3% vs 12.7%(sub-hazard ratio 0.72,95% CI 0.54-0.95;p=0.019)。
  • VA-LRTI患者中多重耐药菌比例72% vs 59%(p=0.011)。
  • VA-LRTI患者ICU死亡率54% vs 30%(OR 2.68,95% CI 1.78-4.02;p<0.0001);VAP亚组死亡率64% vs 34%(p<0.001)。

临床怎么用

  • 免疫抑制机械通气患者VA-LRTI发生率虽低,但需警惕高死亡风险。
  • 对免疫抑制合并VA-LRTI者应关注多重耐药菌覆盖。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aim of this planned analysis of the prospective multinational TAVeM database was to determine the incidence, aetiology and impact on outcome of ventilator-associated lower respiratory tract infections (VA-LRTI) in immunocompromised patients.All patients receiving mechanical ventilation for >48 h were included. Immunocompromised patients (n=663) were compared with non-immunocompromised patients (n=2297).The incidence of VA-LRTI was significantly lower among immunocompromised than among non-immunocompromised patients (16.6% versus 24.2%; sub-hazard ratio 0.65, 95% CI 0.53-0.80; p<0.0001). Similar results were found regarding ventilator-associated tracheobronchitis (7.3% versus 11.6%; sub-hazard ratio 0.61, 95% CI 0.45-0.84; p=0.002) and ventilator-associated pneumonia (9.3% versus 12.7%; sub-hazard ratio 0.72, 95% CI 0.54-0.95; p=0.019). Among patients with VA-LRTI, the rates of multidrug-resistant bacteria (72% versus 59%; p=0.011) and intensive care unit mortality were significantly higher among immunocompromised than among non-immunocompromised patients (54% versus 30%; OR 2.68, 95% CI 1.78-4.02; p<0.0001). In patients with ventilator-associated pneumonia, mortality rates were higher among immunocompromised than among non-immunocompromised patients (64% versus 34%; p<0.001).Incidence of VA-LRTI was significantly lower among immunocompromised patients, but it was associated with a significantly higher mortality rate. Multidrug-resistant pathogens were more frequently found in immunocompromised patients with VA-LRTI.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Moreau AS, Martin-Loeches I, Povoa P, et al. Impact of immunosuppression on incidence, aetiology and outcome of ventilator-associated lower respiratory tract infections. Eur Respir J. 2018. PMID: 29439020. doi:10.1183/13993003.01656-2017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。